1. Scrip
  2. >>Focus On Asia

New Domestic Partnerships Help DualityBio Become China ADC Bellwether

 
• By Dexter Jie Yan

China's Duality Biologics, founded in 2020, has developed two-thirds of its clinical-stage antibody-drug conjugates by combining antibodies acquired from domestic peers with its proprietary linker-payload platform.

alliance
Chinese ADC players increasingly combining strengths in linker-payload platforms and antibodies • Source: Shutterstock

Duality Biologics (DualityBio), one of the Chinese firms making waves on the world antibody-drug conjugate stage since 2022, has revealed four new domestic antibody partnerships that put the fledgling biotech on a course to becoming an ADC bellwether in the country.

Key Takeaways

  • China's DualityBio reveals details of new domestic antibody partnerships that are helping it accelerate the development of four clinical-stage ADCs.

The disclosures came as DualityBio on 26 August filed for an initial public offering on the Hong Kong Stock Exchange,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.